The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies

被引:45
|
作者
Muz, Barbara [1 ]
de la Puente, Pilar [1 ]
Azab, Feda [1 ]
Luderer, Micah [1 ]
Azab, Abdel Kareem [1 ]
机构
[1] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO 63108 USA
关键词
MULTIPLE-MYELOMA CELLS; BONE-MARROW MICROENVIRONMENT; HEMATOPOIETIC STEM-CELLS; ACTIVATED PRODRUG TH-302; NF-KAPPA-B; INDUCIBLE FACTOR-1-ALPHA; IN-VIVO; HODGKIN-LYMPHOMA; LEUKEMIC-CELLS; SOLID TUMORS;
D O I
10.1158/1541-7786.MCR-14-0028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor hypoxia is a well-described phenomenon during the progression of solid tumors affecting cell signaling pathways and cell metabolism; however, its role in hematologic malignancies has not been given the same attention in the literature. Therefore, this review focuses on the comparative differences between solid and hematologic malignancies with emphasis on the role of hypoxia during tumorigenesis and progression. In addition, contribution of the bone marrow and angiogenic environment are also discussed. Insight is provided into the role of hypoxia in metastatic spread, stemness, and drug resistance in hematologic conditions. Finally, emerging therapeutic strategies such as small-molecule prodrugs and hypoxia-inducible factor (HIF) targeting approaches are outlined to combat hypoxic cells and/or adaptive mechanisms in the treatment of hematologic malignancies. (C) 2014 AACR.
引用
收藏
页码:1347 / 1354
页数:8
相关论文
共 50 条
  • [41] Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies
    Jain, Nitin
    Odenike, Olatoyosi
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (18) : 3073 - 3084
  • [42] THE ROLE OF RECOMBINANT INTERLEUKIN-2 IN THERAPY FOR HEMATOLOGIC MALIGNANCIES
    DUTCHER, JP
    WIERNIK, PH
    SEMINARS IN ONCOLOGY, 1993, 20 (06) : 33 - 40
  • [43] The role of myeloid-derived suppressor cells in hematologic malignancies
    Gunes, Emine Gulsen
    Rosen, Steven T.
    Querfeld, Christiane
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (05) : 518 - 526
  • [44] Thioredoxin and Hematologic Malignancies
    An, Ningfei
    Kang, Yubin
    REDOX AND CANCER, PT A, 2014, 122 : 245 - 279
  • [45] Hematologic malignancies in pregnancy
    Hurley, TJ
    McKinnell, JV
    Irani, MS
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2005, 32 (04) : 595 - +
  • [46] Hematologic Malignancies of the Breast
    Alsadi, Alaa
    Murro, Diana
    Martyn, Colin
    Miller, Ira
    Gattuso, Paolo
    LABORATORY INVESTIGATION, 2015, 95 : 33A - 33A
  • [47] Immunotherapy for Hematologic Malignancies
    Craddock, Charles
    Friedberg, Jonathan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (05) : 343 - +
  • [48] Telomerase in hematologic malignancies
    Bruedigam, Claudia
    Lane, Steven W.
    CURRENT OPINION IN HEMATOLOGY, 2016, 23 (04) : 346 - 353
  • [49] Immunotherapy in hematologic malignancies
    Kansara, R. R.
    Speziali, C.
    CURRENT ONCOLOGY, 2020, 27 : S124 - S131
  • [50] The Microbiota in Hematologic Malignancies
    Yajing Song
    Bryan Himmel
    Lars Öhrmalm
    Peter Gyarmati
    Current Treatment Options in Oncology, 2020, 21